![]() ![]() What is an “antidote to Factor Xa inhibitor?” Well, again I tend to reveal my ignorance whenever I talk science… but it’s basically an antidote to the newer variety of anticoagulant drugs like Eliquis and Xarelto (newer, that is, than the low-cost Warfarin that has been in use for a long time, with lots of well-known side effects). And it should be hearing from the FDA very soon on approval, their PDUFA date is indeed August 17 (the PDUFA date is the deadline by which a response from the FDA is expected, it’s not set in stone but the FDA usually gets close). OK, so that’s got to be enough (especially since, as I noted above, a lot of you already know this stock pretty well) - the Thinkolator can confirm that this is, in fact, Portola Pharmaceuticals (PTLA).Īnd yes, it has developed an antidote to Factor Xa inhibitors called Andexxa (Andexanet alfa). Jerrold Levy of Duke University predicts that once available, all hospitals will stock the universal antidote.” “And it’s surrounded by patents… protected from competition for the next 15 years or more. “Let me be clear… it has absolutely NO competition. “By the end of this summer, you could find this one-of-a-kind drug at every hospital across the nation. (I’ll show you why that could even be a conservative guess in just a moment.) “And when it does, I estimate – based on the sales figures alone – that it will surge 8,233% higher. “You see, Lightning is about to strike for this little-known company… ![]() “… if you want a shot at seeing results like these, you must get in before August 17. “It’s capable of achieving results in as little as two minutes… “early trial results show that this drug is immensely effective. “And, thanks to this drug’s dramatic life-changing potential, it’s already been designated as a breakthrough therapy AND has been granted an Accelerated Approval pathway by the FDA…. “It’s based on the results of a 13-year collaboration of award-winning scientists who come from Harvard, Yale, Johns Hopkins and more. And, of course, a “universal antidote” could perhaps save a lot more than 1.5 million people.īut apparently it is an antidote to something that causes “a severe medical event”. That’s essentially impossible (I feel pretty confident saying that, even though I’m too much of a dummy to understand much in the world of biology and drug development). So… does this “universal antidote” mean it will counteract all drugs? Uh, no. An antidote is a counteragent to a drug or a poison (many drugs in the wrong dose or the wrong patient, of course, might be considered poisonous). This is an important point when we should mention what “universal antidote” means, however. There are some pull quotes from doctors and well-known medical journals thrown in at this point, largely to give some weight to the promise - if the New England Journal of Medicine calls it “a potential universal antidote,” the copywriter thinks, that means a lot more than Marc Lichtenfeld calling it a universal antidote. “A miraculous new drug – with an incredible patent moat… and zero competition – is on the brink of eliminating these untimely deaths once and for all…” “Most of these deaths are unrelated to the illness or condition that patients are being treated for…. “One that has NOTHING to do with infection… heart attacks… or even human error…. “Worst of all, many of them are unable to beat this highly preventable cause of death… “… every year, as many as 1.5 million people suffer from a severe medical event – one that requires immediate attention. Geez, that’s only $666 bucks for each life saved! So what is this “universal antidote,” you ask? More clues: “And send the stock soaring 8,233% over the long term… possibly even higher.” “When it does, it could add $1 billion to its revenues… “To put it simply, one under-the-radar company is about to release a “universal antidote” that could likely save up to 1.5 million lives this year… “The greatest biotech stock story of this decade is about to hit the markets right now. Life (and investing) is rarely so simple as that, of course, particularly in the highly volatile world of biotech stocks (exhibit A being Lichtenfeld’s guarantee that ALNY would double when it was around $130… it has instead halved in the biotech washout) … but let’s look into the promise Lichtenfeld is peddling this time… ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |